ERAMET (ER7.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:ER7 - FR0000131757 - Common Stock
49.02 EUR
-4.93 (-9.14%)
ER7 gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 36 industry peers in the Metals & Mining industry. ER7 may be in some trouble as it scores bad on both profitability and health. ER7 is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ER7 had negative earnings in the past year.
In the past year ER7 has reported a negative cash flow from operations.
ER7 had positive earnings in 4 of the past 5 years.
Of the past 5 years ER7 4 years had a positive operating cash flow.
1.2 Ratios
ER7 has a Return On Assets of -1.58%. This is in the lower half of the industry: ER7 underperforms 69.23% of its industry peers.
The Return On Equity of ER7 (-9.29%) is worse than 71.79% of its industry peers.
With a Return On Invested Capital value of 0.80%, ER7 is not doing good in the industry: 76.92% of the companies in the same industry are doing better.
Measured over the past 3 years, the Average Return On Invested Capital for ER7 is in line with the industry average of 8.06%.
The last Return On Invested Capital (0.80%) for ER7 is well below the 3 year average (7.29%), which needs to be investigated, but indicates that ER7 had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROIC | 0.8% |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
1.3 Margins
In the last couple of years the Profit Margin of ER7 has declined.
ER7 has a worse Operating Margin (1.91%) than 74.36% of its industry peers.
ER7's Operating Margin has declined in the last couple of years.
ER7 has a better Gross Margin (68.15%) than 87.18% of its industry peers.
ER7's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% |
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), ER7 is destroying value.
The number of shares outstanding for ER7 has been increased compared to 1 year ago.
The number of shares outstanding for ER7 has been increased compared to 5 years ago.
Compared to 1 year ago, ER7 has an improved debt to assets ratio.
2.2 Solvency
ER7 has an Altman-Z score of 1.07. This is a bad value and indicates that ER7 is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of 1.07, ER7 is not doing good in the industry: 74.36% of the companies in the same industry are doing better.
ER7 has a Debt/Equity ratio of 2.03. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 2.03, ER7 is doing worse than 89.74% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.07 |
ROIC/WACC0.09
WACC8.95%
2.3 Liquidity
ER7 has a Current Ratio of 1.54. This is a normal value and indicates that ER7 is financially healthy and should not expect problems in meeting its short term obligations.
ER7's Current ratio of 1.54 is on the low side compared to the rest of the industry. ER7 is outperformed by 69.23% of its industry peers.
A Quick Ratio of 1.06 indicates that ER7 should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.06, ER7 perfoms like the industry average, outperforming 41.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 |
3. Growth
3.1 Past
ER7 shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -221.18%.
Measured over the past years, ER7 shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -64.00% on average per year.
The Revenue has decreased by -6.91% in the past year.
Measured over the past years, ER7 shows a decrease in Revenue. The Revenue has been decreasing by -4.39% on average per year.
EPS 1Y (TTM)-221.18%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
3.2 Future
The Earnings Per Share is expected to decrease by -58.83% on average over the next years. This is quite bad
Based on estimates for the next years, ER7 will show a quite strong growth in Revenue. The Revenue will grow by 8.00% on average per year.
EPS Next Y-302.65%
EPS Next 2Y-68.14%
EPS Next 3Y-58.83%
EPS Next 5YN/A
Revenue Next Year4.89%
Revenue Next 2Y7.19%
Revenue Next 3Y8%
Revenue Next 5YN/A
3.3 Evolution
The EPS growth rate is stable: in the next years the growth will be about the same than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ER7. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ER7. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ER7 indicates a slightly more expensive valuation: ER7 is more expensive than 69.23% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 14.21 |
4.3 Compensation for Growth
ER7's earnings are expected to decrease with -58.83% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-68.14%
EPS Next 3Y-58.83%
5. Dividend
5.1 Amount
ER7 has a Yearly Dividend Yield of 2.61%.
Compared to an average industry Dividend Yield of 2.77, ER7 pays a bit more dividend than its industry peers.
Compared to an average S&P500 Dividend Yield of 2.41, ER7 has a dividend comparable with the average S&P500 company.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.61% |
5.2 History
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
The earnings of ER7 are negative and hence is the payout ratio. ER7 will probably not be able to sustain this dividend level.
DP-44.33%
EPS Next 2Y-68.14%
EPS Next 3Y-58.83%
FRA:ER7 (11/21/2025, 7:00:00 PM)
49.02
-4.93 (-9.14%)
Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)
Earnings (Next)
Inst Owners12.66%
Inst Owner ChangeN/A
Ins Owners0.17%
Ins Owner ChangeN/A
Market Cap1.41B
Revenue(TTM)2.88B
Net Income(TTM)-97.00M
Analysts52.73
Price Target52.02 (6.12%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.61% |
Yearly Dividend1.51
Dividend Growth(5Y)N/A
DP-44.33%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.21%
PT rev (3m)-9.31%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.21%
EPS NY rev (3m)-15.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-1.13%
Revenue NY rev (3m)-1.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.49 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.35 | ||
| P/tB | 2.61 | ||
| EV/EBITDA | 14.21 |
EPS(TTM)-3.44
EYN/A
EPS(NY)-3.47
Fwd EYN/A
FCF(TTM)-25.76
FCFYN/A
OCF(TTM)-4.59
OCFYN/A
SpS100.31
BVpS36.3
TBVpS18.78
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.58% | ||
| ROE | -9.29% | ||
| ROCE | 1.16% | ||
| ROIC | 0.8% | ||
| ROICexc | 0.95% | ||
| ROICexgc | 1.09% | ||
| OM | 1.91% | ||
| PM (TTM) | N/A | ||
| GM | 68.15% | ||
| FCFM | N/A |
ROA(3y)4.1%
ROA(5y)1.33%
ROE(3y)16.44%
ROE(5y)-1.91%
ROIC(3y)7.29%
ROIC(5y)7.73%
ROICexc(3y)10.98%
ROICexc(5y)11.38%
ROICexgc(3y)12.91%
ROICexgc(5y)13.43%
ROCE(3y)10.76%
ROCE(5y)11.32%
ROICexgc growth 3Y-56.22%
ROICexgc growth 5Y-25.38%
ROICexc growth 3Y-55.33%
ROICexc growth 5Y-24.94%
OM growth 3Y-46.5%
OM growth 5Y-18.83%
PM growth 3Y-61.12%
PM growth 5YN/A
GM growth 3Y-3.21%
GM growth 5Y23.96%
F-Score2
Asset Turnover0.47
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.03 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 10.29 | ||
| Cap/Depr | 403.31% | ||
| Cap/Sales | 21.11% | ||
| Interest Coverage | 0.34 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.54 | ||
| Quick Ratio | 1.06 | ||
| Altman-Z | 1.07 |
F-Score2
WACC8.95%
ROIC/WACC0.09
Cap/Depr(3y)260.42%
Cap/Depr(5y)209.27%
Cap/Sales(3y)18.57%
Cap/Sales(5y)15.29%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-221.18%
EPS 3Y-64%
EPS 5YN/A
EPS Q2Q%-268.75%
EPS Next Y-302.65%
EPS Next 2Y-68.14%
EPS Next 3Y-58.83%
EPS Next 5YN/A
Revenue 1Y (TTM)-6.91%
Revenue growth 3Y-7.18%
Revenue growth 5Y-4.39%
Sales Q2Q%-3.31%
Revenue Next Year4.89%
Revenue Next 2Y7.19%
Revenue Next 3Y8%
Revenue Next 5YN/A
EBIT growth 1Y-51.75%
EBIT growth 3Y-50.34%
EBIT growth 5Y-22.39%
EBIT Next Year19.46%
EBIT Next 3Y25.5%
EBIT Next 5YN/A
FCF growth 1Y-850%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-121.46%
OCF growth 3YN/A
OCF growth 5YN/A
ERAMET / ER7.DE FAQ
What is the fundamental rating for ER7 stock?
ChartMill assigns a fundamental rating of 2 / 10 to ER7.DE.
What is the valuation status for ER7 stock?
ChartMill assigns a valuation rating of 0 / 10 to ERAMET (ER7.DE). This can be considered as Overvalued.
What is the profitability of ER7 stock?
ERAMET (ER7.DE) has a profitability rating of 3 / 10.
How financially healthy is ERAMET?
The financial health rating of ERAMET (ER7.DE) is 2 / 10.
Can you provide the dividend sustainability for ER7 stock?
The dividend rating of ERAMET (ER7.DE) is 2 / 10 and the dividend payout ratio is -44.33%.